Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual MeetingPRNewsWire • 10/12/22
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct ReprogrammingPRNewsWire • 10/03/22
European Medicines Agency Accepts Astellas' Marketing Authorization Application for FezolinetantPRNewsWire • 09/29/22
Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research EffortsPRNewsWire • 09/20/22
Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland ChinaPRNewsWire • 09/04/22
Astellas Pharma, Inc. (ALPMF) Management on Q1 2022 Results Earnings Call TranscriptSeeking Alpha • 08/01/22
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing lossPRNewsWire • 07/05/22
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe DiseasePRNewsWire • 06/26/22
Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North CarolinaPRNewsWire • 06/08/22
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-OncologyPRNewsWire • 06/01/22
Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid CongressPRNewsWire • 05/12/22
Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual MeetingPRNewsWire • 05/05/22
Astellas Pharma, Inc. (ALPMF) CEO Kenji Yasukawa on Q4 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/27/22
Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in AsiaPRNewsWire • 03/14/22
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer PatientsBenzinga • 02/15/22
Astellas Pharma, Inc. (ALPMF) CEO Kenji Yasukawa on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/27/21